Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2013

01-10-2013 | Review Article

Epidemiology and clinical features of systemic vasculitis

Authors: David G. I. Scott, Richard A. Watts

Published in: Clinical and Experimental Nephrology | Issue 5/2013

Login to get access

Abstract

Different vasculitic syndromes present in different age groups. Immunoglobulin (Ig)A vasculitis and Kawasaki disease usually present in children whereas giant cell arteritis (GCA) and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis usually present in the middle aged/elderly. In Northern Europe, granulomatosis with polyangiitis (GPA; Wegener’s) is commoner than microscopic polyangiitis (MPA) and MPA is more common than eosinophilic granulomatosis with polyangiitis (EPGA; Churg−Strauss syndrome). In Southern Europe, MPA is commoner than GPA and in Japan MPA is much more common than GPA. Major differences exist worldwide in ANCA specificity which are not entirely related to different phenotypes. GPA, like GCA, has a cyclical pattern of onset suggesting possible infection as an aetiological agent. International studies have given important clues to possible aetiology including silica dust and infection and genetic influences, as shown by the recently published genome-wide association study which revealed that single-nucleotide polymorphisms associate more strongly with ANCA than clinical syndromes. A brief description of the main clinical features of ANCA-associated vasculitis is also given.
Literature
1.
go back to reference Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013; 65(1):1−11. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013; 65(1):1−11.
2.
go back to reference Watts RA, Scott DGI. Epidemiology of vasculitis. In: Bridges L, Ball G, editors. Vasculitis. 3rd ed. Oxford: Oxford University Press; 2013 (in press). Watts RA, Scott DGI. Epidemiology of vasculitis. In: Bridges L, Ball G, editors. Vasculitis. 3rd ed. Oxford: Oxford University Press; 2013 (in press).
3.
go back to reference Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: summary. Arthritis Rheum. 1990;33:1135–6.PubMedCrossRef Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: summary. Arthritis Rheum. 1990;33:1135–6.PubMedCrossRef
4.
go back to reference Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.PubMedCrossRef Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.PubMedCrossRef
5.
go back to reference Scott DGI, Watts R. Classification and epidemiology of systemic vasculitis. Br J Rheumatol. 1994;33:897–9.PubMedCrossRef Scott DGI, Watts R. Classification and epidemiology of systemic vasculitis. Br J Rheumatol. 1994;33:897–9.PubMedCrossRef
6.
go back to reference Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004;51:92–9.PubMedCrossRef Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004;51:92–9.PubMedCrossRef
7.
go back to reference Watts RA, Mooney J, Skinner J, Scott DGI, MacGregor AJ. The contrasting epidemiology of granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis. Rheumatology. 2012;51:926–31.PubMedCrossRef Watts RA, Mooney J, Skinner J, Scott DGI, MacGregor AJ. The contrasting epidemiology of granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis. Rheumatology. 2012;51:926–31.PubMedCrossRef
8.
go back to reference Watts RA, González-Gay M, Garcia-Porrua C, Lane S, Bentham G, Scott DGI. Geoepidemiology of systemic vasculitis. Ann Rheum Dis. 2001;60:170–2.PubMedCrossRef Watts RA, González-Gay M, Garcia-Porrua C, Lane S, Bentham G, Scott DGI. Geoepidemiology of systemic vasculitis. Ann Rheum Dis. 2001;60:170–2.PubMedCrossRef
9.
go back to reference Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DRW, Scott GDI, Hashimoto H, Nunoi H. Comparison of the epidemiology of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis between Japan and UK. Rheumatology. 2011;50:1916–20.PubMedCrossRef Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DRW, Scott GDI, Hashimoto H, Nunoi H. Comparison of the epidemiology of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis between Japan and UK. Rheumatology. 2011;50:1916–20.PubMedCrossRef
11.
go back to reference Gatenby PA, Lucas RM, Engelson O, Ponsonby AL, Clements M. Anti-neutrophil cytoplasmic antibody associated vasculitis: could geographic patterns be explained by ambient ultraviolet radiation. Arthritis Rheum. 2009;61:1417–24.PubMedCrossRef Gatenby PA, Lucas RM, Engelson O, Ponsonby AL, Clements M. Anti-neutrophil cytoplasmic antibody associated vasculitis: could geographic patterns be explained by ambient ultraviolet radiation. Arthritis Rheum. 2009;61:1417–24.PubMedCrossRef
12.
go back to reference Yashiro M, Muso E, Itoh-Ihara T, et al. Significantly high regional morbidity of MPO-ANCA related angiitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan). Am J Kidney Dis. 2000;35:889–95.PubMedCrossRef Yashiro M, Muso E, Itoh-Ihara T, et al. Significantly high regional morbidity of MPO-ANCA related angiitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan). Am J Kidney Dis. 2000;35:889–95.PubMedCrossRef
13.
go back to reference Lane SE, Watts RA, Bentham G, Innes NJ, Scott DG. Are environmental factors important in primary systemic vasculitis? A case control study. Arthritis Rheum. 2003;48:124–32.CrossRef Lane SE, Watts RA, Bentham G, Innes NJ, Scott DG. Are environmental factors important in primary systemic vasculitis? A case control study. Arthritis Rheum. 2003;48:124–32.CrossRef
14.
go back to reference Knight A, Sandin S, Askling J. Risks and relative risks of Wegener’s granulomatosis among close relatives of patients with the disease. Arthritis Rheum. 2008;58:302–7.PubMedCrossRef Knight A, Sandin S, Askling J. Risks and relative risks of Wegener’s granulomatosis among close relatives of patients with the disease. Arthritis Rheum. 2008;58:302–7.PubMedCrossRef
Metadata
Title
Epidemiology and clinical features of systemic vasculitis
Authors
David G. I. Scott
Richard A. Watts
Publication date
01-10-2013
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2013
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0830-8

Other articles of this Issue 5/2013

Clinical and Experimental Nephrology 5/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine